With the right analysis technology and medical knowledgebase, next-generation DNA sequencing technology can be turned into individualized cancer treatments.

In the field of cancer treatment research, the Konyang University Hospital of South Korea has embraced analytics to spearhead innovations in “precision medicine” to offer personalized treatment for the deadly disease.

As result of an agreement between the hospital and biotech IT firm, molecular pathologists and oncologists will be able to use a special analysis software that helps interpret ‘next-generation DNA Sequencing’ (NGS) data to make better cancer treatment decisions.

The software automatically detects relevant gene variants from molecular information and identifies treatment options based on the molecular profiles and ongoing trials that may be relevant to the patient.

Individualized treatment for better outcomes

The analysis software from biotech firm Molecular Health (MH) matches a patient’s molecular data with data derived from one of the largest-growing and knowledge platforms (Dataome) to derive treatment possibilities aimed at individual genetic traits.

By transforming genomic data into an evidence-based decision support tool, the software enables physicians and molecular pathologists to keep pace with the rapidly growing stock of medical knowledge and thereby create actionable treatments.

The biotech firm’s specialists from the fields of medicine, data science, biology, bioinformatics and software development will work with the Konyang University Hospital to transform big data into a useful tool for next-generation cancer treatments.

Said Yoon Dae-seong, Director of the Cancer Center at Konyang University Hospital: “Precision medicine in cancer care enables personalized treatment through comprehensive analyses of genes, clinical information and drugs. With our NGS system and (the MH software), we have a complete precision-medicine ecosystem that will enable us to provide world-class cancer care.”  

Molecular Health’s APAC spokesperson, Stephan Hettich, noted: “”We are convinced that (our software) can make an important contribution to the personalized care for Korean patients.”